litlas
Log inCreate account

Zigang Dong

Active 1994–2025

250
Papers
26,333
Citations
99
h-index
235
i10-index

Citations

Citations per year for Zigang Dong1992: 1 citations1994: 3 citations1995: 2 citations1996: 9 citations1997: 28 citations1998: 45 citations1999: 112 citations2000: 122 citations2001: 177 citations2002: 242 citations2003: 301 citations2004: 209 citations2005: 233 citations2006: 237 citations2007: 220 citations2008: 264 citations2009: 215 citations2010: 208 citations2011: 332 citations2012: 223 citations2013: 198 citations2014: 200 citations2015: 179 citations2016: 230 citations2017: 181 citations2018: 209 citations2019: 618 citations2020: 723 citations2021: 779 citations2022: 666 citations2023: 556 citations2024: 894 citations2025: 478 citations2026: 15 citations1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,476 citing papers, 23.3% of this breakdownChina: 2,159 citing papers, 20.3% of this breakdownIndia: 480 citing papers, 4.5% of this breakdownSouth Korea: 441 citing papers, 4.2% of this breakdownGermany: 385 citing papers, 3.6% of this breakdownUnited Kingdom: 369 citing papers, 3.5% of this breakdownItaly: 359 citing papers, 3.4% of this breakdownJapan: 299 citing papers, 2.8% of this breakdownCanada: 220 citing papers, 2.1% of this breakdownFrance: 213 citing papers, 2% of this breakdownSpain: 206 citing papers, 1.9% of this breakdownAustralia: 178 citing papers, 1.7% of this breakdown
0%23.3%Other 26.7%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology43.5%
  • Medicine40.2%
  • Pharmacology, Toxicology and Pharmaceutics3%
  • Agricultural and Biological Sciences2.2%
  • Neuroscience2.1%
  • Immunology and Microbiology1.9%
  • Other7.1%

Topics

  • Cancer-related Molecular Pathways2.5%
  • Phytochemicals and Antioxidant Activities2.1%
  • Genomics, phytochemicals, and oxidative stress1.9%
  • Tea Polyphenols and Effects1.7%
  • RNA modifications and cancer1.7%
  • Ubiquitin and proteasome pathways1.7%
  • Other88.4%

Coauthors

All papers

Open in search
  1. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

    Authors: Ruijuan Du, Chuntian Huang, Kangdong Liu, Xiang Li, Zigang Dong - Molecular Cancer 2021 cited by 620

  2. AKT as a Therapeutic Target for Cancer

    Authors: Mengqiu Song, Ann M. Bode, Zigang Dong, Mee‐Hyun Lee - Cancer Research 2019 cited by 804

  3. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

    Authors: Yamei Hu, Zigang Dong, Kangdong Liu - Journal of Experimental & Clinical Cancer Research 2024 cited by 222

  4. Integrins in cancer: Emerging mechanisms and therapeutic opportunities

    Authors: Fangfang Liu, Qiong Wu, Zigang Dong, Kangdong Liu - Pharmacology & Therapeutics 2023 cited by 175

  5. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer

    Authors: Ran Zhao, Bu Young Choi, Mee-Hyun Lee, Ann M. Bode, Zigang Dong - EBioMedicine 2016 cited by 431

  6. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

    Authors: Fangfang Liu, Jingyu Chen, Kai Li, Haochen Li, Yiyi Zhu, Yubo Zhai, Bingbing Lu, Yanle Fan, Ziyue Liu, Xiaojie Chen, Xuechao Jia, Zigang Dong, Kangdong Liu - Molecular Cancer 2024 cited by 267

  7. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2

    Authors: Penglei Wang, Xuechao Jia, Bingbing Lu, Han Huang, Jialin Liu, Xuejiao Liu, Qiong Wu, Yamei Hu, Pan Li, Huifang Wei, Tingting Liu, Dengyun Zhao, Lingwei Zhang, Xueli Tian, Yanan Jiang, Yan Qiao, Wenna Nie, Xinli Ma, Ruihua Bai, Cong Peng, Zigang Dong, Kangdong Liu - Signal Transduction and Targeted Therapy 2023 cited by 93

  8. Post-translational modification of p53 in tumorigenesis

    Authors: Ann M. Bode, Zigang Dong - Nature reviews. Cancer 2004 cited by 1,256

  9. Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery

    Authors: Hui Liu, Kangdong Liu, Zigang Dong - Cancer Research 2020 cited by 97

  10. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer

    Authors: Xueli Tian, Tingxuan Gu, Mee‐Hyun Lee, Zigang Dong - Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021 cited by 141

  11. Targeting LIMK1 with luteolin inhibits the growth of lung cancer in vitro and in vivo

    Authors: Man Zhang, Rui Wang, Jie Tian, Mengqiu Song, Ran Zhao, Kangdong Liu, Feng Zhu, Jung‐Hyun Shim, Zigang Dong, Mee‐Hyun Lee - Journal of Cellular and Molecular Medicine 2021 cited by 66

  12. Molecular mechanisms of green tea polyphenols with protective effects against skin photoaging

    Authors: Eunmiri Roh, Jong‐Eun Kim, Jung Yeon Kwon, Jun Seong Park, Ann M. Bode, Zigang Dong, Ki Won Lee - Critical Reviews in Food Science and Nutrition 2015 cited by 147

  13. Cdc2-like kinases: structure, biological function and therapeutic targets for diseases

    Authors: Mengqiu Song, L. Pang, Mengmeng Zhang, Yingzi Qu, Kyle Vaughn Laster, Zigang Dong - Signal Transduction and Targeted Therapy 2023 cited by 69

  14. Protein translation: biological processes and therapeutic strategies for human diseases

    Authors: Xuechao Jia, Xinyu He, Chuntian Huang, Jian Li, Zigang Dong, Kangdong Liu - Signal Transduction and Targeted Therapy 2024 cited by 124

  15. Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer

    Authors: Xuejiao Liu, Simin Zhao, Keke Wang, Liting Zhou, Ming Jiang, Yunfeng Gao, Ran Yang, Shiwen Yan, Wen Zhang, Bingbing Lu, Fei‐Fei Liu, Ran Zhao, Wenting Liu, Zihan Zhang, Kangdong Liu, Xiang Li, Zigang Dong - Nature Communications 2023 cited by 51

  16. Precision medicine: the foundation of future cancer therapeutics

    Authors: Seung Ho Shin, Ann M. Bode, Zigang Dong - npj Precision Oncology 2017 cited by 132

  17. Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo

    Authors: Hai Huang, Song Park, Haibo Zhang, Sijun Park, Wookbong Kwon, Enugyung Kim, Xiujuan Zhang, Soyoung Jang, Duhak Yoon, Seong‐Kyoon Choi, Junkoo Yi, Sung-Hyun Kim, Zigang Dong, Mee-hyun Lee, Zae Young Ryoo, Myoung Ok Kim - Journal of Experimental & Clinical Cancer Research 2021 cited by 69

  18. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer

    Authors: Xueli Tian, Rui Wang, Tingxuan Gu, Fayang Ma, Kyle Vaughn Laster, Xiang Li, Kangdong Liu, Mee‐Hyun Lee, Zigang Dong - Molecular Cancer 2022 cited by 58

  19. The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications

    Authors: Zheqiong Tan, Xiangjian Luo, Lanbo Xiao, Min Tang, Ann M. Bode, Zigang Dong, Ya Cao - Molecular Cancer Therapeutics 2016 cited by 188

  20. Toxic Phytochemicals and Their Potential Risks for Human Cancer

    Authors: Ann M. Bode, Zigang Dong - Cancer Prevention Research 2014 cited by 141

  21. PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy

    Authors: Qian Luo, Ruijuan Du, Wenting Liu, Guojing Huang, Zigang Dong, Xiang Li - Frontiers in Oncology 2022 cited by 97

  22. Repurposed pizotifen malate targeting NRF2 exhibits anti-tumor activity through inducing ferroptosis in esophageal squamous cell carcinoma

    Authors: Xinyu He, Yubing Zhou, Wenjing Chen, Xiaokun Zhao, Lina Duan, Hao Zhou, Mingzhu Li, Yu Yin, Jimin Zhao, Yaping Guo, Huihui Gu, Yanan Jiang, Zigang Dong, Kangdong Liu - Oncogene 2023 cited by 42

  23. Circulating Tumor Cells: Moving Biological Insights into Detection

    Authors: Lichan Chen, Ann M. Bode, Zigang Dong - Theranostics 2017 cited by 133

  24. Inflammation in cancer: therapeutic opportunities from new insights

    Authors: Yifei Xie, Fangfang Liu, Yunfei Wu, Yuer Zhu, Yanan Jiang, Qiong Wu, Zigang Dong, Kangdong Liu - Molecular Cancer 2025 cited by 93